Achillion Pharma CEO talks up sale amid Hep C trials

Achillion Pharmaceuticals CEO Michael Kishbauch told Bloomberg that his drug development group has entered serious talks with potential partners and parties interested in buying his company, with the firm's board of directors preferring the latter. "We're prepared to be patient and pick the best deal," he told the news service. The firm's lead drug ACH-1625 is in mid-stage development for hepatitis C virus. Article

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.